Drugs in MeSH Category Antithrombins

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	CAPSULE;ORAL	022512-002	Oct 19, 2010	AB	RX	Yes	Yes	7,932,273*PED				Y
Alembic	DABIGATRAN ETEXILATE MESYLATE	dabigatran etexilate mesylate	CAPSULE;ORAL	215233-002	Jun 14, 2024	AB	RX	No	No
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	PELLETS;ORAL	214358-004	Jun 21, 2021		RX	Yes	No	7,932,273*PED				Y
Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate	CAPSULE;ORAL	022512-002	Oct 19, 2010	AB	RX	Yes	Yes	9,034,822*PED				Y
Apotex	DABIGATRAN ETEXILATE MESYLATE	dabigatran etexilate mesylate	CAPSULE;ORAL	208070-001	Dec 15, 2023	AB	RX	No	No

Market dynamics and patent landscape for drugs in MeSH Class: Antithrombins

Last updated: April 25, 2026

What falls under the MeSH “Antithrombins” bucket?

MeSH “Antithrombins” is a therapeutic and mechanistic class centered on anticoagulation via inhibition of thrombin (and related coagulation targets). In practice, this market is dominated by clinically used direct and indirect antithrombin pathways, with a strong split between:

• Direct thrombin inhibitors (DTIs)
• Indirect thrombin inhibition via antithrombin (AT) potentiation (heparins and heparin-like agents)

For market/patent purposes, the most investable and frequently cited branded products mapped to “antithrombins” include:

• Direct thrombin inhibitor: bivalirudin
• Indirect thrombin inhibition (AT-dependent): unfractionated heparin (UFH), low molecular weight heparins (LMWHs), and heparin-like agents
• Oral small molecules often classified elsewhere: many MeSH hierarchies separate “thrombin inhibitors” from “antithrombins,” but industry listings still cluster these mechanisms for competitive analysis

MeSH anchor: “Antithrombins” is defined in the NLM MeSH taxonomy as a drug class category. (See MeSH Browser entry for “Antithrombins”.) [1]

---

How is the antithrombin market moving (demand, setting, and pricing pressure)?

Across anticoagulation, demand is driven by two durable sources:

1. Acute care: peri-procedural anticoagulation (cardiology), VTE/embolism management, and thrombosis risk in hospital settings.
2. Chronic prevention: atrial fibrillation and VTE secondary prevention, where anticoagulant choice tracks bleeding-risk profiles and renal function.

Demand mix that favors “antithrombin” mechanisms

• Hospital systems remain heavy buyers for heparins (UFH/LMWH) due to controllability, monitoring workflows, and formulary inertia.
• Cardiac catheterization and interventional cardiology are where bivalirudin historically held stronger positions because of predictable anticoagulation and workflow fit in procedural pathways. (Competitive dynamics below.)

Pricing pressure and formulary dynamics

• Generic erosion is most significant for older heparin brands and many LMWH presentations over time.
• Formulary protocols reduce brand switching between anticoagulant classes unless a specific clinical pathway mandates it.
• Renal impairment and bleeding risk keep clinicians risk-calibrated, which supports continued use of adjustable-dose injectable anticoagulants even when newer oral options take share elsewhere.

---

What is the competitive landscape by product technology?

The antithrombin-relevant market breaks down into three technology buckets with distinct patent and commercialization behavior:

1) Heparins / heparin-like anticoagulants (AT-dependent)

• Patent reality: many “core” molecules and process claims are older; current competitive intensity comes from generics, authorized generics, and formulation/process patents.
• Adoption: high, due to long-established clinical protocols.

Implication: brand differentiation relies on:

• manufacturing/process improvements,
• device/form factor,
• patient safety claims (where supported by evidence),
• and managed-access contracting.

2) Direct thrombin inhibition (DTIs)

• Key branded example: bivalirudin
• Patent reality: DTIs often reach fewer absolute competitors, but once generics enter, price compression can be rapid.

3) Oral direct thrombin inhibitors

Some oral agents compete for anticoagulation budgets even if taxonomy placement varies. Their net effect on “antithrombins” is competitive substitution at the class level in formularies.

---

Which active patent families shape supply and brand defensibility in this space?

Below is a “useful for investment and R&D planning” view of how patent leverage typically appears for antithrombin mechanisms. The key pattern: the molecule patents decay, while new layers persist around:

• polymorphs/solid forms,
• salts and manufacturing/process,
• manufacturing impurities specs,
• dosing regimen claims,
• delivery-device claims (less common for injectables),
• and method-of-use claims in defined patient subsets.

Practical patent “layers” investors should map

1. Active ingredient composition and process (often expired for older heparins; still active for newer entities or process improvements)
2. Formulation (buffer, excipients, particle size, pH, sterilization, lyophilization)
3. Manufacturing controls and impurities (process parameters, validation strategies)
4. Method of use (specific procedures, dosing strategies, patient subsets)
5. Regulatory exclusivities that extend practical market timing even after composition patents end (varies by jurisdiction)

---

What does the bivalirudin patent lifecycle look like for market defense?

Bivalirudin is the most prominent “antithrombin” branded DTI in interventional cardiology. Competitive timing has historically followed:

• initial composition/process protection,
• subsequent formulation/manufacturing refinements,
• then market entry once key claims fall.

Actionable market consequence: bivalirudin pricing and volume are strongly shaped by whether any “new layer” patents still support exclusivity against biosimilar-style substitutes or generic DTIs (for small molecules, typical generic pathways apply). The practical differentiator is the presence or absence of still-enforceable formulation and method-of-use claims after primary expiration.

---

How do MeSH class boundaries impact patent landscape mapping and analytics?

MeSH “Antithrombins” is taxonomy-driven, not legal classification. For patent landscape work, it creates two recurring errors:

• Under-inclusion: patents for thrombin inhibitors may be categorized under “thrombin inhibitors” MeSH nodes rather than “antithrombins.”
• Over-inclusion: heparin-related patents may appear in “antithrombins” searches but the competitive set in practice includes broader anticoagulation comparators.

Best practice mapping in competitive analysis is to treat MeSH as the starting label and then expand with:

• thrombin inhibition synonyms (direct thrombin inhibitor vs AT-dependent),
• mechanism of action terms,
• and brand-to-ingredient crosswalks from label databases.

(Reference anchor for taxonomy starting point: MeSH Browser entry for “Antithrombins”.) [1]

---

What patent datasets and sources should drive the landscape (for enforceability, not marketing)?

A litigation-leaning patent landscape for “antithrombins” should pull:

• granted patents and active applications,
• legal status (expired, lapsed, pending),
• jurisdictional coverage (US, EP, JP, CN),
• and claim-type filters (composition, method, process).

Core sources used for MeSH class identification and linking:

• NLM MeSH Browser for class definition and search term boundaries. [1]
• FDA Orange Book for US exclusivity and active ingredient linkages (for small molecules and many combination products).
• EPO/USPTO family mapping for global claim coverage and priority chains.
• Patent analytics platforms for legal status events and maintenance.

Because you asked for NLM MeSH class dynamics and patent landscape, the mandatory taxonomy anchor is the MeSH entry. [1]

---

Where is the “next IP” likely to come from in antithrombin drugs?

Even when composition patents expire, antithrombin-related IP tends to regenerate through:

1) Formulation and manufacturing differentiation

• improved purity and impurity profile,
• stability improvements (shelf-life and stress stability),
• process controls that reduce lot-to-lot variability.

2) Method-of-use differentiation

• narrow patient cohorts,
• specific procedure pathways,
• dosing regimens tied to outcomes in defined populations.

3) Delivery optimization (more limited for heparins, more relevant in special formulations)

• ready-to-use presentations,
• infusion regimen optimization,
• sterile packaging improvements that reduce administration errors (where claimable).

---

Key takeaways

• MeSH “Antithrombins” is a taxonomy-defined bucket, and it should be treated as the starting point for patent mapping, then expanded to thrombin inhibitor and anticoagulation comparator families for completeness. [1]
• Market demand remains anchored in acute hospital use and cardiology/procedural pathways, with long-lived protocol inertia supporting heparin use even when oral anticoagulants gain share.
• Patent defensibility in this space typically shifts after primary molecule expiry toward formulation/process and method-of-use layers that extend practical market exclusivity.
• Bivalirudin illustrates how enforceable claim layers shape substitution timing once primary protections end, making “last surviving” formulation and use patents the most investable screen for near-term brand defense.

---

FAQs

1) How should “Antithrombins” be used in a patent landscape?

Use MeSH “Antithrombins” as the initial label set, then expand via mechanism and ingredient crosswalks to avoid missing thrombin-inhibitor families that sit in adjacent MeSH nodes. [1]

2) What most often drives patent leverage after molecule patents expire in this class?

Claim-layer shifts toward formulation/manufacturing controls and method-of-use in defined procedures or patient subsets.

3) Which clinical setting most strongly sustains demand for heparin/DTI-type antithrombins?

Hospital acute care, especially procedural cardiology and thrombosis management workflows with established protocols.

4) Does competitive pressure usually come from within the same MeSH class?

Often yes at the ingredient/mechanism level (heparins vs DTIs), but formulary substitution and outcome-based selection also pull in oral anticoagulant competitors even if MeSH placement differs.

5) For investment screening, what is the fastest way to identify “defensibility cliffs”?

Track (i) composition/process claim expiry by jurisdiction, then (ii) identify remaining active formulation and method-of-use claim families that align with current branded dosing and approved procedural indications.

---

References

[1] National Library of Medicine. (n.d.). MeSH Browser: Antithrombins. https://meshb.nlm.nih.gov/